Evofem Biosciences, Inc.
EVFM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $19 | $18 | $17 | $8 |
| % Growth | 6.3% | 8.2% | 104.2% | – |
| Cost of Goods Sold | $4 | $7 | $4 | $4 |
| Gross Profit | $16 | $12 | $12 | $4 |
| % Margin | 80.2% | 64.3% | 73.8% | 50.8% |
| R&D Expenses | $2 | $3 | $25 | $33 |
| G&A Expenses | $12 | $15 | $28 | $25 |
| SG&A Expenses | $21 | $27 | $72 | $138 |
| Sales & Mktg Exp. | $9 | $12 | $44 | $113 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $23 | $30 | $97 | $171 |
| Operating Income | -$8 | -$18 | -$84 | -$167 |
| % Margin | -39.6% | -98% | -499.6% | -2,023.3% |
| Other Income/Exp. Net | -$1 | $71 | $7 | -$38 |
| Pre-Tax Income | -$9 | $53 | -$77 | -$205 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | $53 | -$77 | -$205 |
| % Margin | -45.8% | 290.8% | -455.5% | -2,489% |
| EPS | -0.092 | 10.36 | -164.59 | -2,962.49 |
| % Growth | -100.9% | 106.3% | 94.4% | – |
| EPS Diluted | -0.092 | 0.051 | -164.59 | -2,962.49 |
| Weighted Avg Shares Out | 96 | 5 | 0 | 0 |
| Weighted Avg Shares Out Dil | 96 | 984 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $2 | $2 | $1 |
| EBITDA | -$7 | -$16 | -$82 | -$166 |
| % Margin | -35.7% | -88.2% | -487.5% | -2,010.9% |